🫁 Lung-only metastatic PDAC: a distinct subgroup? ejcancer.com/article/S0959-… 🎯 11% of metastatic PDAC had lung-only metastases 🧬 Less KRAS/TP53 detected in liquid biopsy 🎯 mOS 28.7 months vs 13.5 months (liver-only) and 11.3 months (other sites), p<0.0001 🛠️ Local treatments →

For decades, KRAS, MYC, TP53, WNT were called “undruggable.” That era is ending. This Annals of Oncology review shows how platform science is cracking them: tri-complex inhibitors, PROTACs, mini-proteins, bispecific immune redirection. 🔓 KRAS G12D Zoldonrasib (RMC-9805) shows

Si un médico quiere su profesión, se nota; si no la quiere, se nota más. Es un dato que no consta el el currículum vitae. Solo lo conocen sus pacientes.

New paper online!📃 Largest multicenter Spanish series on SBRT for localized PCa, conducted across GenesisCare España centers. Part of Sigfredo Romero thesis; proud to be your supervisor. 🔗 rdcu.be/e2PbY Fernando Lopez Campos Constantinos Zamboglou David Sanz Rosa Filippo Alongi

𝗡𝗮𝗽𝗿𝗼𝘅𝗲𝗻 ◦ Naproxen has been consistently observed to possess a "neutral" or significantly lower risk of causing heart attacks and strokes compared to other NSAIDs such as diclofenac or ibuprofen at high doses. ◦ Several meta-analyses, including that of the CNT

From metformin to basal insulin to overlooked older medications, the latest episode of Beyond Journal Club, a collaboration between CORE IM and NEJM Group, reviews the T2D medication toolkit clinicians use every day. The hosts then dive into new evidence on once-weekly

Data from global sotorasib expanded access programs JTO & JTO CRR in KRAS G12C NSCLC (n=268). Real world PFS 6.3m, OS 9.5m, similar in PS 0-1 vs 2 and +/- brain metastases. 58% of PS2 improved to PS 0-1 after 1 cycle. Most common TRAE was diarrhea at 31%. jtocrr.org/article/S2666-…

• In Febrile Neutropenia, the enemy isn’t the most common bug. • It’s the one that kills first. • Why we prioritise Gm-neg & anti-pseudomonal cover • Why Gm pos- isn’t routine • Why the first 60 minutes matter 👇 #FebrileNeutropenia #Antibiotics #EmergencyMedicine #MVOnco

La vocación no la inventó el trabajador sino el patrón, como herramienta de control de aquél, y es casi perfecta: 👉🏻 no requiere imposición, el trabajador desea ser reconocido como encadenado por su vocación 👉🏻 se autoperpetúa, el trabajador encadenado se la impone a sus pares

Here the link to the BCLC 2025 model authors.elsevier.com/c/1mZTWcOnAYVAl. The CUSE approach informs options to consider according to strength of evidence. Individualized decision making with patient involvement. Hospital Clínic ILCA Asociación Española Contra el Cáncer EASLnews

Cuando el diagnóstico no encaja. linkedin.com/posts/lisardo-…

linkedin.com/posts/lisardo-…

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

🫁📌NUEVA GUÍA 2026 AHA/ACC : Manejo del Tromboembolismo Pulmonar Agudo (TEP) Nuevos cambios claves que transforman la práctica clínica 👇🧵 1️⃣ Cambio FUNDAMENTAL: Nueva Clasificación Clínica AHA/ACC 🆕 Se abandona la vieja división de “masivo/submasivo” y se introduce: 🔹

In recurrent or metastatic #NasopharyngealCancer, tislelizumab plus chemotherapy led to longer overall survival and durable progression-free survival compared with placebo plus chemotherapy. ja.ma/4secchj

¿Recuerdas cuando te uniste a X? ¡Yo sí! #MiAniversarioDeX

🫁 Amivantamab + Lazertinib in Atypical EGFR NSCLC: CHRYSALIS-2. In 105 pts with advanced NSCLC harboring atypical EGFR mutations (G719X, L861Q, S768I), Amivantamab + Lazertinib achieved: • ORR 52% • mPFS 11.1 mo • mDoR 14.1 mo • mOS NE Tx-naïve: ORR 57%, mPFS 19.5 mo.

🫁 A potential new vulnerability in oncogene-driven NSCLC. MTAP loss - a metabolic alteration present in ~10-15% of cancers - appears particularly frequent in EGFR, ALK and RET driven lung cancers. A new Annals of Oncology study explores its biological and therapeutic

Are we ready for deintensification adjuvant IO in early-stage 🫁? In the future molecular and pathological parameters will guide our decisions? For pCR after induction CTIO we can discuss surveillance and in no-pCR probably continuing the same IO not the besst approach #ELCC26

🚨 New ASCO Guidelines: Thyroid Cancer (2026) Not “which drug?” 👉 It’s now “which mutation?” 🧠 Differentiated (RAI-refractory) No mutation → Lenvatinib > Sorafenib Progression → Cabozantinib Mutation → RET → Selpercatinib NTRK → Larotrectinib BRAF → Dabrafenib +